dronabinol has been researched along with 7,10,13,16-docosatetraenylethanolamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fowler, CJ; Lambert, DM | 1 |
| Griffin, G; Hanus, L; Mechoulam, R; Pertwee, R | 1 |
1 review(s) available for dronabinol and 7,10,13,16-docosatetraenylethanolamide
| Article | Year |
|---|---|
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
Topics: Amides; Amidohydrolases; Amines; Animals; Arachidonic Acids; Binding Sites; Cannabinoid Receptor Modulators; Drug Design; Endocannabinoids; Esters; Ethers; Glycerides; Humans; Ligands; Monoacylglycerol Lipases; Polyunsaturated Alkamides; Receptors, Cannabinoid | 2005 |
1 other study(ies) available for dronabinol and 7,10,13,16-docosatetraenylethanolamide
| Article | Year |
|---|---|
Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia.
Topics: Animals; Dronabinol; Drug Interactions; Drug Tolerance; Electric Stimulation; Ethanolamines; Fatty Acids, Unsaturated; In Vitro Techniques; Male; Mice; Muscle Contraction; Polyunsaturated Alkamides; Structure-Activity Relationship; Vas Deferens | 1994 |